Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator)

MLA

Usha Panchapakesan, et al. “Nanomedicines in the Treatment of Anemia in Renal Disease: Focus on CERA (Continuous Erythropoietin Receptor Activator).” International Journal of Nanomedicine, vol. 2, no. 1, Mar. 2007, pp. 33–38. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....29ffb815a6ac72a0e25b5d5dc14c7c23&authtype=sso&custid=ns315887.

APA

Usha Panchapakesan, Siska Sumual, & Carol A. Pollock. (2007). Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator). International Journal of Nanomedicine, 2(1), 33–38.

Chicago

Usha Panchapakesan, Siska Sumual, and Carol A. Pollock. 2007. “Nanomedicines in the Treatment of Anemia in Renal Disease: Focus on CERA (Continuous Erythropoietin Receptor Activator).” International Journal of Nanomedicine 2 (1): 33–38. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....29ffb815a6ac72a0e25b5d5dc14c7c23&authtype=sso&custid=ns315887.